Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 7/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 7/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 7/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17774687 | 0.87 | GFER (0.58) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL17774643 | 0.86 | GFER (0.57) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL17774669 | 0.83 | GFER (0.54) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL9983954 | 0.77 | GFER (0.63) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL14322837 | 0.77 | PBRM1 (0.45) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL17774587 | 0.76 | MAPT (0.57) | GFERALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL11107477 | 0.76 | GFER (0.81) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL17774553 | 0.75 | MAPT (0.59) | GFERALDH1A1MAPTTP53CYP1A2 | |
| SCHEMBL17774624 | 0.75 | MAPT (0.59) | GFERALDH1A1MAPTTP53CYP1A2 | |
| SCHEMBL17774685 | 0.74 | AKR1C3 (0.48) | GFERALDH1A1MAPTPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872822-B2 | Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition | L'OREAL (FR) | 2018-01-23 | — | — | US | disclosed |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | L'OREAL (FR) | 2016-05-26 | — | — | US | disclosed |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | L'OREAL (FR) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | KRT18, ARSA, SQOR | GFER 56/4885SMARCA2 1534/4885SMARCA4 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.